Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients

Hypertension

Volumn 55, Issue 4, 2010, Pages 819-831

  Staessen, Jan A ^a,b   Richart, Tom ^a,b   Wang, Zengwu ^c   Thijs, Lutgarde ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c FUWAI HOSPITAL   (China)

Author keywords

Antihypertensive drugs; Clinical trials; Hypertension; Outcome research; Primary prevention; Secondary prevention

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG HALF LIFE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SHORT SURVEY; SYNCOPE; SYSTOLIC BLOOD PRESSURE; AGE; DRUG COMBINATION; REVIEW; RISK FACTOR;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77950514137     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.122879     Document Type: Short Survey

References (92)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
2. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
3. The Hope Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12: 127-137.
4. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Forte J, Hamdy R, Henry JF, Joossens JV, Leonetti G, Lund-Johansen P, O'Malley K, Petrie J, Strasser T, Tuomilehto J, Williams B. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;325:1349-1354.
5. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
6. SHEP Cooperative Research Group. Prevention of stroke by antihyper-tensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
7. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [published correction appears in Lancet. 1997;350:1636]. Lancet. 1997; 350:757-764.
8. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velaquez EJ, Weber MA. Rationale and design of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial. Am J Hypertens. 2004;17:793-801.
9. Weber MA, Bakris GL, Dahlöf B, Pitt B, Velaquez E, Gupte J, Lefkowitz M, Hester A, Nessbit S, Ofili E, Jamerson K, for the ACCOMPLISH investigators. Baseline characteristics in the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007;16:13-19.
10. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velaquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ö stergren J, Ibsen H, Weber M, for the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Investigators. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH Study. Blood Press. 2008;17:7-17.
11. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velaquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen JE, Cushman W, Papademetriou V, Weber M, for the ACCOMPLISH investigators. Exceptional early blood pressure control rates: the ACCOMPLISH Trial. Blood Press. 2007;16: 80-86.
12. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velaquez EJ, for the ACCOMPLISH Trial investigators. Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359: 2417-2428.
13. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44: 1118-1120.
14. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet. 2007;370:829-840.
15. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
16. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L, on behalf of the Hypertension in the Very Elderly Trial (HYVET) Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409-2417.
17. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol of the main trial. Drugs Aging. 2001;18:151-164.
18. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovski V, Antikainen R, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
19. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C, for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683-689
20. The ONTARGET/TRANSCEND investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subject with Cardiovascular Disease. Am Heart J. 2004;148: 52-61.
21. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
22. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, on behalf of the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
23. Diener HC, Sacco R, Yusuf S, for the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23:368-380.
24. Yusuf S, Diener HC, Sacco RL, Cotton D, Öunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, for the PRoFESS Study Group. Telm-isartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237.
25. Sacco RL, Diener HC, Yusuf S, Cotton D, Ö unpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts D, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, for the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
26. Diener HC, Sacco RL, Yusuf S, Cotton D, Ô unpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, for the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;874-884
27. The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
28. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-1576.
29. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, for the DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-1393.
30. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, for the DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised placebo-controlled trials. Lancet. 2008;372:1394-1402.
31. Oparil S, Yarrows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet. 2007;370:221-229.
32. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma S, Lewsey J, for the Aliskiren of Heart Failure Treatment (ALOFT) Investigators. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1: 17-24.
33. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Luka-shevich V, Cherif Papst C, Smith BA, Dahlöf B, for the Aliskiren in Left Ventricular Hypertophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-537.
34. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
35. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J, for the INDANA Group. Antihy-pertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet. 1999;353:793-796.
36. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker-Boudier HAJ, Zanchetti A, for the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:1462-1536.
37. Chobanian AV, Bakris GL, Black BK, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
38. Staessen JA, Thijs L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed anti-hypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847-857.
39. Carter BC, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlortha-lidone. Evidence supporting their interchangeability. Hypertension. 2004; 43:3-9.
40. Ernst ME, Carter BC, Goerdt CJ, Steffensmeier JJG, Bryles Phillips B, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
42. Ramsay LE, Yeo WW, Chadwick IG, Jackson PR. Diuretics. In: Swales JD, ed. Textbook of Hypertension. Oxford, United Kingdom: Blackwell Scientific Publications; 1994:1046-1058.
43. Hernández-Hernández R, Armas de Hernández MJ, Armas-Padilla MC, Carvajal AR, Guerrero-Pajuelo J. The effect of missing dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press Monit. 1996;1:121-126.
44. 1 receptor antagonists enhance stroke prevention? Stroke. 2002;881-882.
45. 1-receptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst. 2001;2:103-106.
46. Unger T. Inhibiting renin-angiotensin in the brain: the possible therapeutic implications. Blood Press. 2001;1(suppl):12-16.
47. Garattini S, Bertelé V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007;370:1875-1877.
48. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581-588.
49. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-1160.
50. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder R, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S, for the ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009;120:1380-1389.
51. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattabigio R, Borgioni C, Bentivoglio M, Porcellati C, Ambrosio G. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-652.
52. Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL, for the ONTARGET Investigators. Left ventricular mass and volume with telm-isartan, ramipril, or combination in patients with previous atherosclerotic events or with diabtes mellitus (from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol. 2009;104:1484-1489.
53. Staessen J, Amery A, Fagard R. Editorial review: isolated systolic hypertension in the elderly. J Hypertens. 1990;8:393-405.
54. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903-1913
55. Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension. 2003;42:69-75.
56. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315
57. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
58. Verdecchia P, Reboldi G, Angeli A, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-392.
59. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-958.
60. Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi GP. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2008;30:679-688.
61. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for the primary and secondary prevention of stroke. Hypertension. 2006;48:187-195.
62. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch Intern Med. 2007;167:1930-1936.
63. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;346: 1449-1456.
64. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;295: 485-489
65. Hypertension-Stroke Cooperative Study Group. Effect of antihyper-tensive treatment on stroke recurrence. JAMA. 1974;229:409-418.
66. PATS Collaborative Group. Post-stroke antihypertensive treatment study: a preliminary result. ChinMedJ. 1995;108:710-717.
67. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet. 2001;358: 1033-1041
68. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient isachemic attack or nondisabling stroke. Stroke. 1993;24:543-548.
69. Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group. Atenolol in the secondary prevention of stroke. Cerebrovasc Dis. 1995; 5:21-25.
70. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324:1-5.
71. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens. 2003;21: 875-886. (Pubitemid 36677151)
72. Liu L, Zhao Y, Liu G, Li W, Zhang X, Zanchetti A, for the FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157-2172.
73. Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, Wang J. Blood pressure lowering for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32: 1032-1040.
74. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction: these drugs may increase myocardial infarction-and patients need to be told. BMJ. 2004;329:1248-1249.
75. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angio-tensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet. 2003;362:772-776. (Pubitemid 37093917)
76. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an amlodipine±perindopril strategy compared with an atenolol ±thiazide strategy: the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
77. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, for the Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Arch Intern Med. 2003;138:542-549.
78. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihyper-tensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
79. Whelton PK, Barzilay J, Cushman WC, Davis BR, Ilamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, for the ALLHAT Collaborative Research Group. Clinical outcomes in antihy-pertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401-1409.
80. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Platt F, Schork A, Smith B, Zanchetti A, for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan-or amlodipine-based regimens: VALUE, a randomised trial. Lancet. 2004; 363:2022-2031.
81. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562.
82. Padwal R, Varney J, Majumdar SR, McAllister FA, Johnson JA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabet Care. 2005;28:736-744.
83. Chalmers I, Glasziou P. Avoidable waste in the production and reporting research evidence. Lancet. 2009;374:86-89.
84. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357: 1191-1194. (Pubitemid 32378696)
85. Staessen J, Bulpitt CJ, Clement D, de Leeuw P, Fagard R, Fletcher A, Forette F, Leonetti G, Nissinen A, O'Malley K, Tuomilehto J, Webster J, Williams BO. The relationship between mortality and treated blood pressure in elderly hypertensives. BMJ. 1989;298:1552-1556.
86. Wingfield D, Cooke J, Thijs L, Staessen JA, Fletcher AE, Fagard R, Bulpitt CJ, on behalf of the Syst-Eur Investigators. Terminal digit preference in the Syst-Eur Trial. Blood Press Monit. 2002;7:169-178.
87. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, Babeanu S, Casiglia E, Filipovsky J, Nachev C, Nikitin Y, Peleská J, O'Brien E, on behalf of the EPOGH Investigators. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit. 2002;7:215-224.
88. Myers M, Godwin M. Algorithms for diagnosing hypertension in the office: translating principles into practice. J Hypertens. 2009;27:1746-1747.
89. Staessen JA, Thijs L, Ohkubo T, Kikuya M, Richart T, Boggia J, Adiyaman A, Dechering DG, Kuznetsova T, Thien T, de Leeuw P, Imai Y, O'Brien E, Parati G. Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Press Monit. 2008;13:352-365.
90. Thompson M, Heneghan C, Perera R. Telmisartan in high-risk patients intolerant of ACE inhibitors. Lancet. 2009;373:457-458.
91. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of the UKPDS data. BMJ. 2000;320:1720-1723.
92. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009;361:712-717.